NICE will be appraising these 2 PARP inhibitors at the end of the year for approval for NHS availability and they have asked for nominated patient experts. The names of the appraisals are:
Niraparib as maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy
Rucaparib for treating relapsed ovarian, fallopian tube or peritoneal cancer
that has a BRCA mutation
A patient expert would need to be willing to submit a personal statement about their experience and to attend the NICE committee meeting in London on Tuesday 5 December 2017.
If you have been treated with either of these drugs and think you might like to contribute to the NICE appraisal process please let me know by emailing me email@example.com and I will contact you to discuss the process in more detail.
I'm away on leave next week (24-28 July 2017) but if you send me an email I will get in contact the following week.
Support Service Manager